A phase I study of EDO S101 for the treatment of solid tumours

Trial Profile

A phase I study of EDO S101 for the treatment of solid tumours

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2015

At a glance

  • Drugs EDO S101 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2015 According to the media release of the Mundipharma EDO GmbH, the company was granted INDA approval form FDA for its first anti-cancer compound EDO-S101 indicated for the treatment of relapsed/refractory haematologic malignancies and solid tumours and plans to develop this study in 2015 once the dose escalation part of the first in human study has been completed
    • 09 Jun 2015 New trial record
    • 03 Jun 2015 According to a company media release, Mundipharma plans to initiate this study in 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top